(HealthDay)—For children with X-linked hypophosphatemia, subcutaneous burosumab is associated with decreases in rickets severity and with improved renal tubular phosphate
Continue reading »Home »
mypharmacynews.com
Home »
(HealthDay)—For children with X-linked hypophosphatemia, subcutaneous burosumab is associated with decreases in rickets severity and with improved renal tubular phosphate
Continue reading »